We are live on ! Find out more

Travere Therapeutics

TVTX

Market cap $4.99B

51.99 USD

+0.36

0.7%

At close Updated Nov 10, 4:00 PM EST

Pre-market

After hours

51.00

-0.99

1.9%

1 day

0.7%

5 days

3.42%

1 month

-0.06%

3 months

-14.62%

6 months

19.49%

Year to date

31.55%

1 year

51.22%

5 years

75.11%

10 years

146.75%

About: Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Employees: 497

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 27.3%

Neutral 59.1%

Negative 13.6%

Travere Therapeutics to Participate at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ETUBS Global Biopharma ConferencePresenting on Monday, November 16, 2026, at 11:20 a.m. GMTJefferies London Healthcare ConferencePresenting.

Travere Therapeutics to Participate at Upcoming Investor Conferences

Investors Business Daily

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari.

Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Travere Therapeutics, Inc. (TVTX) Q3 2026 Earnings Call Transcript

Zacks Investment Research

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Travere (TVTX) Q3 Earnings

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.

What Travere Therapeutics (TVTX) Said on Its Q3 Earnings Call

Zacks Investment Research

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $0.28 per share a year ago.

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Travere Therapeutics Reports Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. “Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “We remain early in reaching the more than 100,000 a.

Travere Therapeutics Reports Third Quarter 2026 Financial Results

Travere Therapeutics to Report Third Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. F.

Travere Therapeutics to Report Third Quarter 2026 Financial Results

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO.“These biomarker data provide new insight into how FILSPARI's dual mechanism of action may modify the unde.

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Zacks Investment Research

Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline

See News Rankings

Price charts implemented using Lightweight Charts™